Live/Dead Staining for Quantifying Viable but Not Culturable Cells in Manuka Honey-Treated Wound-Causing Bacteria

Lyric T Baker1, Bryn Tennyson1, Andrea R Castillo2

  • 1Department of Biology, Eastern Washington University.

Insights

Manuka Honey (MH) may combat antibiotic resistance by inducing fewer dormant (Viable But Not Culturable or VBNC) bacterial cells compared to conventional antibiotics. This study suggests MH is a promising alternative antimicrobial agent.

Area of Science:

  • Microbiology
  • Antimicrobial Resistance
  • Bacterial Physiology

Background:

  • Antibiotic resistance and bacterial dormancy (Viable But Not Culturable - VBNC state) are major global health threats.
  • Conventional antibiotics can induce bacterial dormancy, reducing their efficacy.
  • Manuka Honey (MH) exhibits broad-spectrum antimicrobial activity with low resistance development.

Purpose of the Study:

  • To investigate if Manuka Honey (MH) induces fewer VBNC cells than conventional antibiotics.
  • To evaluate MH's potential as an alternative antimicrobial agent to circumvent antibiotic resistance.
  • To establish a protocol for assessing VBNC induction by antimicrobials.

Main Methods:

  • Developed a protocol to treat Staphylococcus aureus and Pseudomonas aeruginosa with MH, tobramycin, or meropenem at minimum inhibitory concentrations.
  • Utilized viable plate counts and live/dead staining to quantify culturable and total viable cells.
  • Compared the induction of VBNC cells across different treatments.

Main Results:

  • Only P. aeruginosa treated with tobramycin showed a significant increase in VBNC cells compared to viable cells.
  • No significant increase in VBNC cells was observed for MH or meropenem treatments.
  • The developed protocol is rapid and effective for evaluating VBNC induction.

Conclusions:

  • Manuka Honey (MH) appears to induce fewer VBNC cells than the conventional antibiotic tobramycin.
  • MH demonstrates potential as an alternative antimicrobial agent that may overcome antibiotic resistance mechanisms.
  • The findings support further investigation of MH for treating bacterial infections, particularly those involving VBNC-inducing pathogens.

Related Concept Videos